CStone Pharmaceuticals (2616) H1 2024 earnings summary

Executive summary

• Achieved first-ever profitability in H1 2024, with net profit of RMB15.7 million, reversing a loss of RMB209.2 million in H1 2023, driven by licensing income, cost control, and increased gross profit.

• Total revenue for H1 2024 was RMB254.2 million, down 2.8% year-over-year, as higher license fee income offset lower product sales.

• Major pipeline and commercial milestones include EU approval for sugemalimab, new strategic partnerships, and multiple regulatory submissions.

• Maintains a robust pipeline with four commercialized products and multiple late-stage and early-stage assets.

• Expanded international presence with EU approval for sugemalimab and strategic partnerships in Europe and China.

Financial highlights

• H1 2024 revenue was RMB254.2 million (down 2.8% YoY); license fee income up RMB122.6 million, product sales down RMB128.6 million.

• Net profit reached RMB15.7 million, with adjusted profit (excluding share-based payments) of RMB10.8 million.

• Gross profit was RMB172.0 million, up from RMB153.4 million year-over-year.

• Cash and cash equivalents stood at RMB813.9 million as of June 30, 2024.

• No interim dividend declared for H1 2024.

Outlook and guidance

• Anticipates UK approval for sugemalimab in H2 2024 and global market launches in early 2025.

• Multiple IND submissions and new clinical trials for pipeline assets planned through 2025.

• Ongoing cost discipline and focus on high-value projects expected to support continued profitability.